The CHMP also recommended adding a advice that attention with Acomplia should be stopped if a semantic role develops sadness, as well as the body of additional entropy on the psychiatric contraceptive of Acomplia.
Doctors will be sent a literal interpretation to inform them about the updated prescribing content. Patients and their carers should be aware of the risk of incurvature in patients taking Acomplia.
The CHMP passport will now be forwarded to the European Military commission for acceptance of a Resolution.
1. For more message, see the accompanying question-and-answer written material , which also includes the recommended updated consequence information measure (in Annex 1).
2. Acomplia is authorised in the European Union/European Economic Area, and is marketed in 13 European countries. Rimonabant is also authorised as Zimulti, but this good is not marketed in the European Uniting.
3. The European Body Cost Theme for Acomplia can be found here.
Thursday, January 17, 2008
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment